STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMMP
  4. [Form 3] IMMUTEP Ltd Initial Statement of Beneficial Ownership

Immutep (IMMP) CMO reports Ordinary Shares and performance rights

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

IMMUTEP Ltd Chief Medical Officer Stephan Karel Gerard Winckels filed an initial ownership report showing his equity position. He directly holds 92,935 Ordinary Shares and three blocks of 221,708 performance rights each over Ordinary Shares, with vesting dates in 2026, 2027 and 2028 and an exercise price of $0.0000. The vesting of these performance rights depends on achieving specified key performance indicators and they expire in 2030.

Positive

  • None.

Negative

  • None.
Insider Winckels Stephan Karel Gerard
Role Chief Medical Officer
Type Security Shares Price Value
holding Performance rights (right to receive) -- -- --
holding Performance rights (right to receive) -- -- --
holding Performance rights (right to receive) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Performance rights (right to receive) — 221,708 shares (Direct); Ordinary Shares — 92,935 shares (Direct)
Footnotes (1)
  1. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2026 and the vesting of the remaining 443,416 performance rights is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2027 and the vesting of the remaining 221,708 performance rights is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2028 and the vesting is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date.
Ordinary Shares held 92,935 shares Direct ownership following Form 3 report
Performance rights tranche 1 221,708 underlying shares Vesting on December 1, 2026, exercise price $0.0000
Performance rights tranche 2 221,708 underlying shares Vesting on December 1, 2027, exercise price $0.0000
Performance rights tranche 3 221,708 underlying shares Vesting on December 1, 2028, exercise price $0.0000
Exercise price of performance rights $0.0000 per share Performance rights over Ordinary Shares
Performance rights expiration October 13, 2030 Expiration date for all three performance-rights blocks
Performance rights (right to receive) financial
"security_title": "Performance rights (right to receive)""
Ordinary Shares financial
"underlying_security_title": "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
key performance indicators financial
"vesting is dependent on Mr. Winckels achieving key performance indicators"
Key performance indicators are specific measurements used to track how well a person, team, or organization is achieving its goals. They act like report cards, providing clear signs of progress or areas needing improvement. For investors, KPIs help assess the health and future potential of a business by highlighting its most important strengths and challenges.
Chief Medical Officer financial
"officer_title": "Chief Medical Officer""
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Winckels Stephan Karel Gerard
(Last)(First)(Middle)
LEVEL 32, AUSTRALIA SQUARE,
264 GEORGE STREET
(Street)
SYDNEY, NEW SOUTH WALESAUSTRALIA2000
(City)(State)(Zip)
AUSTRALIA
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
IMMUTEP Ltd [ IMMP ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares92,935D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance rights (right to receive)(1)12/01/202610/13/2030Ordinary Shares221,708$0D
Performance rights (right to receive)(2)12/01/202710/13/2030Ordinary Shares221,708$0D
Performance rights (right to receive)(3)12/01/202810/13/2030Ordinary Shares221,708$0D
Explanation of Responses:
1. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2026 and the vesting of the remaining 443,416 performance rights is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date.
2. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2027 and the vesting of the remaining 221,708 performance rights is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date.
3. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2028 and the vesting is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date.
Stephan Karel Gerard Winckels04/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider position did IMMUTEP (IMMP) disclose for Stephan Winckels?

IMMUTEP disclosed that Chief Medical Officer Stephan Winckels directly holds 92,935 Ordinary Shares. He also holds three tranches of 221,708 performance rights over Ordinary Shares, each vesting between 2026 and 2028, subject to key performance indicators and expiring in 2030.

Did the IMMUTEP (IMMP) Form 3 show any insider share purchases or sales?

The Form 3 reflects initial ownership for Stephan Winckels and does not show any explicit buy or sell transactions. It reports existing holdings of Ordinary Shares and performance rights, with transaction direction fields marked as unknown and no purchase or sale codes indicated.

How many Ordinary Shares does IMMUTEP CMO Stephan Winckels hold?

Stephan Winckels directly holds 92,935 Ordinary Shares of IMMUTEP. This figure comes from the holding entry listing Ordinary Shares with total shares following the report of 92,935. No indirect ownership or related-entity holdings are disclosed in the provided data.

What performance rights over IMMUTEP (IMMP) shares does the CMO hold?

The CMO holds three positions of 221,708 performance rights each over IMMUTEP Ordinary Shares. These rights have a zero exercise price, vest on December 1 of 2026, 2027 and 2028 respectively, and expire on October 13, 2030, subject to achieving key performance indicators.

What are the vesting conditions for IMMUTEP performance rights held by the CMO?

The performance rights were granted on October 13, 2025 and vest on set dates if key performance indicators are met. One 221,708 block vests December 1, 2026, another on December 1, 2027, and another on December 1, 2028, with vesting explicitly tied to performance criteria.

What is the exercise price and expiry of IMMUTEP CMO performance rights?

Each block of performance rights over IMMUTEP Ordinary Shares carries an exercise price of $0.0000. According to the disclosure, these rights share an expiration date of October 13, 2030, meaning they must vest and be exercised, if eligible, before that date.